Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie ABBV in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 5 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 3 | 4 | 1 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $213.08, a high estimate of $239.00, and a low estimate of $190.00. Marking an increase of 2.44%, the current average surpasses the previous average price target of $208.00.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive AbbVie. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tim Anderson | B of A Securities | Raises | Neutral | $223.00 | $200.00 |
| Geoff Meacham | Citigroup | Raises | Buy | $215.00 | $205.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $217.00 | $211.00 |
| Navin Jacob | UBS | Raises | Neutral | $190.00 | $181.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $210.00 | $195.00 |
| Terence Flynn | Morgan Stanley | Raises | Overweight | $239.00 | $224.00 |
| Gary Nachman | Raymond James | Raises | Outperform | $220.00 | $218.00 |
| Vamil Divan | Guggenheim | Raises | Buy | $214.00 | $212.00 |
| Evan David Seigerman | BMO Capital | Raises | Outperform | $215.00 | $208.00 |
| Geoff Meacham | Citigroup | Lowers | Buy | $205.00 | $215.00 |
| Srikripa Devarakonda | Truist Securities | Lowers | Buy | $211.00 | $215.00 |
| Christopher Raymond | Piper Sandler | Raises | Overweight | $220.00 | $212.00 |
| Tim Anderson | B of A Securities | Announces | Neutral | $191.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AbbVie. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AbbVie compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for AbbVie's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AbbVie's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on AbbVie analyst ratings.
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Financial Milestones: AbbVie's Journey
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining AbbVie's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.6% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -0.21%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): AbbVie's ROE excels beyond industry benchmarks, reaching -0.68%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.02%, the company may face hurdles in achieving optimal financial returns.
Debt Management: AbbVie's debt-to-equity ratio is notably higher than the industry average. With a ratio of 20.19, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
